Previous 10 | Next 10 |
2023-08-10 08:06:33 ET More on Johnson & Johnson Future Prospects For Johnson & Johnson Following Strong Q2 Performance Johnson & Johnson: Resilient, But Clarification On Liability Issue Is Needed Johnson & Johnson ( JNJ ) Q2 2023 Earnings Call ...
2023-08-08 22:52:07 ET Ligand Pharmaceuticals Incorporated (LGND) Q2 2023 Earnings Conference Call August 8, 2023 16:30 ET Company Participants Simon Latimer - Head, Investor Relations Todd Davis - Chief Executive Officer Tavo Espinoza - Chief Financial Officer ...
2023-08-08 17:42:33 ET Ligand Pharmaceuticals press release ( NASDAQ: LGND ): Q2 Non-GAAP EPS of $1.42 beats by $0.76 . Revenue of $26.4M (-47.3% Y/Y) beats by $0.67M . For further details see: Ligand Pharmaceuticals Non-GAAP EPS of $1.42 beats by $0.76, ...
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a confere...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its collaborator Merck, known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, an investigational 21-valent pneumococcal conjugate vaccine in vaccin...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2023 financial results after the close of the U.S. financial markets on Tuesday, August 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a gener...
Ligand provides bridge and debtor-in-possession ("DIP") financing to Novan Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 m...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE NEWSWIRE) -- S...
2023-06-22 03:29:44 ET Summary The article discusses the recent developments and transformation of Ligand Pharmaceuticals. It follows up on a previous article from 12/2022 titled "A New Ligand Is Taking Shape". The focus is on the company's growth, new strategies, and potentia...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-09 10:30:11 ET Craig-Hallum analyst issues BUY recommendation for LGND on July 9, 2024 08:42AM ET. The previous analyst recommendation was Buy. LGND was trading at $86.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-07-09 10:00:05 ET Matt Hewitt from Craig-Hallum issued a price target of $140.00 for LGND on 2024-07-09 08:42:00. The adjusted price target was set to $140.00. At the time of the announcement, LGND was trading at $86.88. The overall price target consensus is at $117...
Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the b...